<DOC>
	<DOCNO>NCT01152801</DOCNO>
	<brief_summary>This open-label , multi-center study evaluate safety RAD001 Chinese patient metastatic renal cell cancer intolerant progress despite treatment vascular endothelial growth factor ( VEGF ) -targeted therapy . All patient treat RAD001 10 mg daily tumor progression ( determine accord Response Evaluation Criteria In Solid Tumors ( RECIST ) Criteria ) , unacceptable toxicity , death discontinuation study reason . At least 60 patient enrol study . Screening baseline evaluation perform within 28 day date patient sign inform consent form . Baseline evaluation perform within two week first dose RAD001 . Screening baseline evaluation perform determine patient meet inclusion exclusion criterion . All eligible patient enrol study receive first dose RAD001 ( 10 mg daily ) Day 1 , Cycle 1 . Subsequently , patient ask come clinic every month complete protocol-specified evaluation . A treatment Cycle consist 28 day . After discontinuation treatment RAD001 , patient safety follow-up perform 28 day last dose RAD001 . Patients must continue survival assessment perform every 3 month last dose RAD001 2 year last patient 's first visit date . An interim analysis focus safety data final analysis data plan . All patient still receive study drug time final analysis give option continue treatment RAD001 occurrence unacceptable toxicity disease progression .</brief_summary>
	<brief_title>Safety RAD001 Chinese Patients With Metastatic Renal Cell Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients Chinese origin ≥ 18 year old . Patients histologically cytologically confirm metastatic renal cell carcinoma . Patients intolerant progression stop treatment VEGFtargeted therapy within 6 month . Note : Prior treatment vaccine therapy adjuvant set prior treatment cytokine ( i.e. , IL2 , Interferon ) chemotherapy permit . Patients least 1 measurable lesion determine accord RECIST Criteria Guidelines . Patients history brain metastasis clinically judge investigator neurologically stable follow definitive radiation surgery require corticosteroid may enrol study . Patients Karnofsky Performance Status ≥ 70 % . Patients adequate bone marrow function define ANC ≥ 1.5 x 109/L , Platelets ≥ 100 x 109/L , Hgb &gt; 9 g/dL . Patients adequate liver function define serum bilirubin ≤ 1.5 x ULN , ALT AST ≤ 2.5x ULN . Patients know liver metastasis AST ALT ≤ 5x ULN . Patients adequate renal function define serum creatinine ≤ 2 x ULN . Women childbearing potential must negative serum pregnancy test within 14 day prior administration RAD001 . Patients must give write informed consent accord local guideline Patients receive chemotherapy , immunotherapy , radiotherapy investigational agent ( include pazopanib , axitinib ) within 4 week study entry , receive sunitinib® and/or sorafenib® within 2 week first dose RAD001 . Patients previously receive RAD001 mTOR inhibitor . Patients know hypersensitivity RAD001 rapamycin analog ( sirolimus , temsirolimus ) , excipients . Patients history another primary malignancy ≤ 3 year , exception nonmelanoma skin cancer , carcinoma situ uterine cervix . Patients receive chronic systemic treatment corticosteroid another immunosuppressive agent . Patients may receive low dose treatment corticosteroid maximum dose 20 mg prednisone 10 mg dexamethasone per day , give disorder rheumatoid arthritis , asthma , adrenal insufficiency . Topical inhale corticosteroid permit . Patients clinically significant active bleeding diathesis . Patients know HIV seropositivity , hepatitis B C seropositivity . Patients prior hepatitis B vaccination may enter study review hepatitis test result investigator . Patients undergone major surgery within 4 week prior start study drug ( e.g. , intrathoracic , intraabdominal , intrapelvic ) , open biopsy , significant traumatic injury , recover side effect . Patients severe and/or uncontrolled medical condition : unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction ≤ 6 month , serious uncontrolled cardiac arrhythmia , uncontrolled hypercholesterolemia ( &gt; 300 mg/dL 7.75 mmol/L ) , uncontrolled diabetes ( fast glucose &gt; 2x ULN ) , active uncontrolled severe infection , cirrhosis , chronic persistent active hepatitis . Female patient pregnant breast feeding , adult reproductive potential use effective birth control method . If barrier contraceptive use , must continue throughout study sex , 8 week end treatment . Hormonal contraceptives acceptable sole method contraception Other protocol relate inclusion/exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>mRCC ,</keyword>
	<keyword>everolimus ,</keyword>
	<keyword>mTOR ,</keyword>
	<keyword>intolerant VEGF-therapies</keyword>
</DOC>